[1]EuropeanJournalofMedicinalChemistry,1989,vol.24,p.233-240
[1]Lee,JinSoo;Oh,YoonSeok;Lim,JaeKyung;Yang,WangYong;Kim,IkHoe;Lee,ChiWoo;Chung,YongHo;Yoon,SungJune[SyntheticCommunications,1999,vol.29,#14,p.2547-2557]
[1]Cossy,Janine;Molina,JoseL;Desmurs,Jean-Roger[TetrahedronLetters,2001,vol.42,#33,p.5713-5715]
[1]Cossy,Janine;Molina,JoseL;Desmurs,Jean-Roger[TetrahedronLetters,2001,vol.42,#33,p.5713-5715]
Title: Toga, T., Y. Kohmura, and R. Kawatsu, The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. J Pharmacol Sci, 2007. 105(2): p. 207-10.
Title: Sung, K.W. and S.J. Hahn, Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol, 2013. 386(10): p. 905-16.
Title: Mine, Y, et al. Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro. J Pharmacol Exp Ther, 1997. 283(3): p. 1000-8.
Title: Motavallian, A, et al., Does Cisapride, as a 5HT(4) Receptor Agonist, Aggravate the Severity of TNBS-Induced Colitis in Rat. Gastroenterol Res Pract, 2012. 2012: p. 362536.